Print full article

FDA approves new drug for diabetic dogs

Boehringer Ingelheim’s ProZinc must be prescribed by a licensed veterinarian

Suggested Veterinary Products

A new drug for managing diabetes mellitus in dogs has been approved for use in the U.S.

The U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine has cleared Boehringer Ingelheim’s ProZinc (protamine zinc recombinant human insulin) as a safe and effective drug to reduce hyperglycemia (high blood sugar) and associated clinical signs in diabetic dogs.

The drug has already been approved for use in cats. Prior to the approval, veterinarians prescribed the feline product to dogs under off-label use.

The administration warns ProZinc should not be used in dogs who are sensitive to protamine zinc recombinant human insulin or any of its other ingredients, or during episodes of hypoglycemia (low blood sugar).

The most common adverse reactions in dogs taking ProZinc were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking, diarrhea, and ataxia.

FDA advises use of an approved animal insulin drug product for newly diagnosed dogs or when transitioning pets from one product to another.


Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.